(Q40121515)

17 September 2017

title

Measuring the public-health impact of candidate HIV vaccines as part of the licensing process (English)

1 reference

17 September 2017

0 references

2

1 reference

17 September 2017

Benoit Masse

4

0 references

Marie-Claude Boily

object named as

Marie-Claude Boily

series ordinal

1

0 references

Roy M. Anderson

series ordinal

6

object named as

Roy Anderson

1 reference

17 September 2017

Kamal Desai

3

1 reference

17 September 2017

Steve Self

series ordinal

5

1 reference

17 September 2017

publication date

1 March 2008

1 reference

Lancet Infectious Diseases

17 September 2017

published in

1 reference

17 September 2017

volume

8

1 reference

17 September 2017

issue

3

1 reference

17 September 2017

page(s)

200-207

1 reference

Study designs for evaluating different efficacy and effectiveness aspects of vaccines

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

On individual and population effectiveness of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Potential public health impact of imperfect HIV type 1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Overview of vaccine field studies: types of effects and designs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV prevention trial outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Complementary hypothesis concerning the community sexually transmitted disease mass treatment puzzle in Rakai, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

The Impact of a Partially Effective HIV Vaccine on a Population of Intravenous Drug Users in Bangkok, Thailand: A Dynamic Model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Modeling the impact of imperfect HIV vaccines on the incidence of the infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Could disease-modifying HIV vaccines cause population-level perversity?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Statistical issues in the design of HIV vaccine trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Simulation studies of phase III clinical trials to test the efficacy of a candidate HIV-1 vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Some important issues in the planning of phase III HIV vaccine efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Augmented designs to assess immune response in vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

On the analysis of viral load endpoints in HIV vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Meta-analysis for the evaluation of potential surrogate markers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Sensitivity Analysis for the Assessment of Causal Vaccine Effects on Viral Load in HIV Vaccine Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Partner-specific sexual behavioral differences between phase 3 HIV vaccine efficacy trial participants and controls: Project VISION

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Sexual risk factors associated with volunteering for HIV vaccine research in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Will sexual risk behaviour increase after being vaccinated for AIDS?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Implementation of audio computer-assisted interviewing software in HIV/AIDS research

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Audio computer-assisted self-interviewing in reproductive health research: reliability assessment among women in Harare, Zimbabwe

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Palmtop-assisted self-interviewing for the collection of sensitive behavioral data: randomized trial with drug use urine testing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

The feasibility of audio computer-assisted self-interviewing in international settings.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Induction of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses in HIV vaccine trial participants who subsequently acquire HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

HIV-1 envelope evolution and vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Imperfect vaccines and herd immunity to HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Quantifying HIV-1 transmission due to contaminated injections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Uncertainty in predictions of disease spread and public health responses to bioterrorism and emerging diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

Public health considerations for the use of a first generation HIV vaccine. Report from a WHO-UNAIDS-CDC consultation, Geneva, 20-21 November 2002

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2807%2970292-X

7 January 2021

10.1016/S1473-3099(07)70292-X

Identifiers

DOI

1 reference

17 September 2017

1 reference